Artificial intelligence (AI) in smart buildings and infrastructure represents the integration of advanced computational systems into the design, operation, and management of built environments and critical public works.

The global AI in semiconductor devices market encompasses the design, fabrication, and integration of specialized hardware engineered to execute artificial intelligence workloads efficiently. This includes a spectrum of silicon solutions, such as Graphics Processing Units (GPUs), Field Programmable Gate Arrays (FPGAs), and Application Specific Integrated Circuits (ASICs), including Neural Processing Units (NPUs). These devices are architected to accelerate machine learning and deep learning algorithms, enabling rapid data processing directly on the hardware.

Global AI in semiconductor automated test equipment analysis market refers to the integration and application of artificial intelligence technologies, such as machine learning (ML), deep learning (DL), and advanced analytics, within the market for automated test equipment used in semiconductor manufacturing and testing. This market focuses on the use of AI to enhance the efficiency, accuracy, and predictive capabilities of ATE systems, which are specialized computer-controlled systems designed to test and analyze the functionality, performance, and reliability of semiconductor devices, including integrated circuits (ICs), memory chips, and other electronic components

The global AI in RPA market encompasses the integration of cognitive technologies, such as machine learning, natural language processing, and computer vision, with RPA platforms. This convergence, often termed Intelligent Automation, enhances the capabilities of traditional RPA, which is primarily designed for automating repetitive, rules-based tasks involving structured data.

医疗器械板块25Q3收入增速转正，利润同比下滑幅度环比收窄明显。随着集采政策影响逐步出清、库存和基数压力逐步减弱、美对中关税缓和、出海和新产品新业务逐步放量，多家公司的业绩有望持续改善，26年相比25年业绩加速；短期建议关注板块业绩改善背景下的结构性投资机会，长期建议关注创新、出海、并购整合的机会。医疗服务板块25Q3收入同比小幅下滑，部分消费医疗服务公司客单价企稳回升，严肃医疗服务公司业绩仍受多重政策影响而承压。

2025至今医药板块震荡上行。2025Q2受关税影响深度调整，关税阴影解除后受创新药出海预期影响震荡上行。医药板块估值溢价率为268.64%，达到历史 74.00%分位，高于历史平均溢价率237.04%，处于2010年以来的相对中位，Q3有所回落。25Q3医药主题基金规模创新高，各板块行业龙头地位稳固。行业数据方面，我国基本医保基金收支稳健增长，在医药支付端提供稳定支撑。国内创新药资产全球认可度快速提升，BD交易量价齐升，Top MNC对国内创新药资产关注度持续上升；器械招采增速较Q2高位有所回落，但整体仍处于稳健增长姿态。

继续推荐创新药械及产业链。维持以下 A 股标的增持评级：恒瑞医药、科伦药业、华东医药、长春高新、恩华药业、药明康德、泰格医药、乐普医疗、联影医疗、惠泰医疗，相关标的：众生药业。并将上述标的纳入国泰海通医药 2025 年 11 月月度组合。维持以下 H 股标的增持评级：翰森制药、三生制药、科伦博泰生物、康方生物、 映恩生物，百济神州、相关标的：信达生物、药明康德。

老龄化、城镇化、疾病谱的变化使得医药行业成为永恒的朝阳行业。全指医药在经历了2022-2024年三年回调后，2025年表现优异，主要得益于创新药板块供给需求双向奔赴，以及医疗器械板块内需逐步复苏、外需强劲增长。未来，需求和供给仍将是医药行业研究的主要逻辑。

医药上市公司已完成2025年三季度业绩披露。整体看，2025年前三季度，医药行业整体营收及扣非净利润分别同比下滑1.98%和11.60%，仍然承压，但降幅较上半年有所收窄。分子行业看，生物制药上游、医疗信息化、CRO/CMO、科研试剂等板块的扣非净利润增速排序靠前；生物制药上游、CRO/CMO、医疗设备和家用器械板块呈现收入和扣非归母净利润的双重增长。

集采负面影响基本出清，龙头企业长期前景可期。目前脊柱类、创伤 和关节类器械等骨科植入物已经被陆续纳入集采范围之中。2024 年人工关节进行了集采续约，整体价格体系基本稳定，膝关节产品意向采购量显著增长，新一代含陶瓷材质髋关节产品占比提升，体现出集采降价后，临床终端实现了以价换量和产品的升级换代。长期看，骨科 疾病发病率与年龄相关度较高，随着我国老龄化趋势延续，预计骨科手术量和骨科植入物的需求量持续稳健增长。骨科植入物行业具有较高的进入壁垒，我们认为行业竞争格局整体较为稳定，龙头企业有望 长期保持领先地位。